solid phase direct label RIA using, e.g., 125 I label {see, e.g., Morel et al, (1988) Mol
Water, Glycerin, Caprylic/Capric Triglyceride, Butylene Glycol, Methylpropanediol, Niacinamide, Tranexamic Acid, Dipropylene Glycol, Phenyl Trimethicone, 1,2-Hexanediol, Butyrospermum Parkii (Shea) Butter, Cetearyl Alcohol, Dicaprylyl Carbonate, Polyglyceryl-2 Stearate, Polysorbate 60, Glyceryl Stearate, Stearyl Alcohol, Sorbitan Sesquioleate, Sodium Polyacrylate, Stearic Acid, Lactose, Ammonium Acryloyldimethyltaurate / VP Copolymer, Microcrystalline Cellulose, Palmitic Acid, Betaine, Caprylic/Capric Triglyceride, Ethylhexylglycerin, Sodium Acrylate/Sodium Acryloyldimethyl Taurate Copolymer, Propanediol, Allantoin, Adenosine, Polyisobutene, Tocopherol, Hydrogenated Lecithin, Disodium EDTA, Astaxanthin, CI 77491, Tocopheryl Acetate, Phytosteryl/Octyldodecyl Lauroyl Glutamate, Arachidic Acid, Caprylyl / Capryl Glucoside, Sorbitan Oleate, Ceramide NP, Eriobotrya Japonica Leaf Extract, Theobroma Cacao (Cocoa) Extract, Myristic Acid, Oleic Acid, Glutathione, Hydroxypropyl Methylcellulose, Mentha Viridis (Spearmint) Extract, CI 14700, Ascorbic Acid, Sodium Hyaluronate, Dextrin
Emerging nanotherapeutics for antithrombotic treatment
Dosage range: Reported ranges vary widely, but most experimental use falls between 100 mcg 500 mcg per injection
